- Home
- FPI vs IMAB Comparison
FPI vs IMAB Comparison
Compare FPI & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FPI
- IMAB
- Stock Information
- Founded
- FPI 2013
- IMAB 2014
- Country
- FPI United States
- IMAB United States
- Employees
- FPI N/A
- IMAB 32
- Industry
- FPI Real Estate Investment Trusts
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- FPI Real Estate
- IMAB Health Care
- Exchange
- FPI Nasdaq
- IMAB Nasdaq
- Market Cap
- FPI 478.7M
- IMAB 384.6M
- IPO Year
- FPI 2014
- IMAB 2020
- Fundamental
- Price
- FPI $11.04
- IMAB $5.09
- Analyst Decision
- FPI
- IMAB Strong Buy
- Analyst Count
- FPI 0
- IMAB 4
- Target Price
- FPI N/A
- IMAB $6.75
- AVG Volume (30 Days)
- FPI 400.7K
- IMAB 4.7M
- Earning Date
- FPI 07-23-2025
- IMAB 08-20-2025
- Dividend Yield
- FPI 2.18%
- IMAB N/A
- EPS Growth
- FPI 229.01
- IMAB N/A
- EPS
- FPI 1.21
- IMAB N/A
- Revenue
- FPI $55,000,000.00
- IMAB N/A
- Revenue This Year
- FPI N/A
- IMAB N/A
- Revenue Next Year
- FPI N/A
- IMAB N/A
- P/E Ratio
- FPI $9.15
- IMAB N/A
- Revenue Growth
- FPI N/A
- IMAB N/A
- 52 Week Low
- FPI $9.66
- IMAB $0.60
- 52 Week High
- FPI $12.87
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- FPI 54.44
- IMAB 68.67
- Support Level
- FPI $10.76
- IMAB $4.13
- Resistance Level
- FPI $10.95
- IMAB $5.90
- Average True Range (ATR)
- FPI 0.17
- IMAB 0.66
- MACD
- FPI 0.04
- IMAB 0.09
- Stochastic Oscillator
- FPI 83.33
- IMAB 72.73
About FPI Farmland Partners Inc.
Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).